Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Agents: Other

Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors

Jarrod Longcor, Anatoly Pinchuk, Randall Hoover and John Friend
Jarrod Longcor
1Cellectar Biosciences Inc, Florham Park, CT;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anatoly Pinchuk
2Cellectar Biosciences, Inc, Florham Park, NJ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall Hoover
3Cellectar Biosciences Inc, Florham Park, NJ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Friend
3Cellectar Biosciences Inc, Florham Park, NJ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-19-C070 Published December 2019
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA

Abstract

Lipid rafts (LR) are specialized regions or microdomains within the cell membrane that are highly enriched with cholesterol and sphingolipids. The presence of LR in tumor cell membranes is as much as 10 fold higher than in normal tissue. Our phospholipid ether (PLE) molecules [18-(p-iodophenyl)octadecyl phosphocholine] have a high affinity for binding and being transported into cells via LRs(1). In this study, we report the development of CLR 180099, a LR targeting phospholipid-drug conjugate (PDC), consisting of a PLE with a cleavable peptide linker (non-cathepsin cleavage) bound to a flavagline (FLV) analogue, a highly potent inhibitor of cell proliferation and simulator of apoptosis. We first study the presence of LR on a large panel of cancer cell lines. Then, we evaluated the uptake of multiple PLE conjugates in a similar panel of cancer cell lines. Then CLR 180099 was assessed for uptake and the release of the FLV in in vitro tumor cell lines. Finally, we present a series in vitro anti-proliferation assays in multiple cell lines and in vivo tolerability as compared to free FLV and efficacy of CLR 180099 in HCT 116 colorectal cancer xenograft. Presence of LR was found to be determinant in the sensitivity of tumor cells to the cytotoxic effect of the PDC. Importantly, CLR 180099 demonstrated significant improvement in tolerability of FLV versus free FLV. These results suggest that PLEs could be used to make PDCs that improve tolerability and efficacy of the warhead molecule. The ability to specifically deliver a variety of warheads/payloads to a broad range of tumor cells offers a unique advantage of PDCs. These findings support the continued development of CLR 180099 PDC as a novel targeted therapy. The PDC described in this abstract is investigational, as efficacy and safety have not been established. There is no guarantee that this PDC will be available commercially.

Citation Format: Jarrod Longcor, Anatoly Pinchuk, Randall Hoover, John Friend. CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C070. doi:10.1158/1535-7163.TARG-19-C070

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 18 (12 Supplement)
December 2019
Volume 18, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors
Jarrod Longcor, Anatoly Pinchuk, Randall Hoover and John Friend
Mol Cancer Ther December 1 2019 (18) (12 Supplement) C070; DOI: 10.1158/1535-7163.TARG-19-C070

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors
Jarrod Longcor, Anatoly Pinchuk, Randall Hoover and John Friend
Mol Cancer Ther December 1 2019 (18) (12 Supplement) C070; DOI: 10.1158/1535-7163.TARG-19-C070
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Therapeutic Agents: Other

  • Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic
  • Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
Show more Therapeutic Agents: Other

Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

  • Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic
  • Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers
  • Abstract C070: CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors
Show more Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement